drugset / Trial / NCT06659705

Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)

NCT06659705 ↗

Phase 2 Recruiting 35 enrolled Institut Curie
NaSingle-groupOpen-labelDiagnostic

Summary

Assessment of the relevance of a new medical imaging test, FAPI PET, which could detect progression or relapse earlier than other tests currently available. Ultimately, it could enable early forms of pancreatic cancer to be detected and used for screening. In addition to the usual examinations prescribed, FAPI PET scans will be repeated at several points in the treatment process. All study patients must first have been included in the Homing cohort (NCT 04363983, APHP promotion). Clinical characteristics, judgement criteria and results of biological or imaging examinations carried out as part of this cohort will be shared. Patient follow-up and participation in the study ends when conventional imaging (CT and MRI) shows disease progression, relapse or death.

Timeline

Start
2025-12-02
Primary completion
2029-08-04
Completion
2030-08-08

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-FAPI-46 Diagnostic / imaging agent — —